New opioid aims to cut Post-Surgery nausea without sacrificing pain relief

NCT ID NCT07691086

First seen Jul 08, 2026 · Last updated Jul 09, 2026 · Updated 1 time

Summary

This study compares two painkillers—tegileridine and sufentanil—given as a single shot after laparoscopic surgery in people at high risk of postoperative nausea and vomiting (PONV). The goal is to see if tegileridine, a newer opioid designed to cause fewer side effects, can provide effective pain relief while reducing nausea and vomiting within the first 24 hours after surgery. The trial includes 800 adults aged 18–75 with an Apfel score of 3 or higher, indicating high PONV risk. Researchers will also monitor other side effects like itching, dizziness, and breathing problems.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Tegileridine fumarate injection
What this could lead to
If tegileridine works better, it could offer a way to manage pain after surgery with less nausea and vomiting, improving recovery and comfort for high-risk patients.
What could go wrong
This is an observational study, not a randomized controlled trial, so results may be less definitive. Tegileridine is still being studied, and its benefits over existing opioids are not yet proven.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ENHANCED RECOVERY AFTER SURGERY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Postoperative Nausea and Vomiting

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.